Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fibroblast growth factor 21 (FGF 21) in preparation of drugs for treating acute pancreatitis

A technology for fibroblasts and acute pancreatitis, applied in the field of biomedicine, can solve problems such as the application of fibroblast growth factor 21 that has not yet been seen, and achieve the effect of high safety and promoting cell proliferation.

Pending Publication Date: 2019-08-27
WENZHOU MEDICAL UNIV +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, only the application of FGF21 in acute liver failure and alcoholic fatty liver (patent publication number: CN105214069A) and the application of fibroblast growth factor-21 mature peptide in the preparation of drugs for the treatment of liver fibrosis (patent publication number: CN105288592A ), there is no relevant report on the application of fibroblast growth factor 21 in acute pancreatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fibroblast growth factor 21 (FGF 21) in preparation of drugs for treating acute pancreatitis
  • Application of fibroblast growth factor 21 (FGF 21) in preparation of drugs for treating acute pancreatitis
  • Application of fibroblast growth factor 21 (FGF 21) in preparation of drugs for treating acute pancreatitis

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0070] FGF21 can relieve the symptoms of acute pancreatitis

[0071] Use 10 -8 Ceruletide at mol / l induces rat pancreatic exocrine cells (AR42J) for 2h to establish a cell model of acute pancreatitis (AP).

[0072] Set up the control group (control), which is the untreated rat pancreatic exocrine cells; the model group (Ceruletide), is the acute pancreatitis (AP) model cell; the treatment group (FGF21+Ceruletide) is the acute pancreatitis (AP) model The cells were treated with 100ng / ml FGF21 at the same time.

[0073] The changes of amylase (AMS) and interleukin-6 (IL-6) in the cell supernatant of each group, as well as the changes of the protein content of inflammatory factors IL-6 and TNF-α in the cells of each group were detected. The result is figure 1 As shown,

[0074] figure 1 A and B are the concentration changes of amylase (AMS) and interleukin-6 (IL-6) in the cell supernatant, respectively, and C is the protein expression changes of IL-6 and TNF-α in the cell. Figure, D an...

experiment example 2

[0082] C57BL / 6 mice were divided into control group (Control), model group (Ceruletide), and treatment group (Ceruletide+FGF21).

[0083] No treatment in the control group;

[0084] In the model group, Ceruletide was used to stimulate the establishment of a mouse model of acute pancreatitis. The method was as follows: Ceruletide at 50 μg / kg was injected into the intraperitoneal cavity of the mouse 7 times with an interval of 1 hour.

[0085] In the treatment group, mice were intraperitoneally injected with 1mg / kg of FGF21 protein (developed by the New Drug Research and Development Department of the Pilot Base of the School of Pharmacy, Wenzhou Medical University, human source, serial number AAQ89444.1) during the second injection of Ceruletide. Group processing is consistent.

[0086] The mice were sacrificed, the pancreas was collected, and HE staining was performed after weighing; blood samples of the mice were collected to detect the changes in the levels of AMS and IL-6 in the ser...

experiment example 3

[0096] C57BL / 6 mice were divided into control group (Control), model group (Ceruletide), treatment group (Ceruletide+FGF21), Sirt1 protein inhibition and treatment group (Sirt1-RNAi+Ceruletide+FGF21).

[0097] No treatment in the control group;

[0098] In the model group, a mouse model of acute pancreatitis was established by Ceruletide stimulation according to the method in Experimental Example 2. The method was: 50 μg / kg Ceruletide was injected into the mouse abdominal cavity 7 times with an interval of 1 hour.

[0099] In the treatment group, mice were intraperitoneally injected with 1mg / kg of FGF21 protein (developed by the New Drug Research and Development Department of the Pilot Base of the School of Pharmacy, Wenzhou Medical University, human source, serial number AAQ89444.1) during the second injection of Ceruletide. Group processing is consistent.

[0100] In the Sirt1 protein inhibition and treatment group, mice were intraperitoneally injected with Sirt1 protein RNA interfe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a drug composition for treating acute pancreatitis and application thereof. The composition comprises a fibroblast growth factor 21 (FGF 21), and the fibroblast growth factor 21is used individually or is jointly used with other accessories as an active ingredient. The fibroblast growth factor 21 or the drug composition containing the fibroblast growth factor 21 can be usedfor treating acute pancreatitis, does not antagonize functions of other members of FGF family, and the use safety is very high.

Description

Technical field [0001] The present invention relates to a new application of fibroblast growth factor 21 (FGF21), in particular, to a new application of FGF21 for the treatment of acute pancreatitis, and belongs to the field of biomedicine technology. Background technique [0002] The pancreas is one of the important digestive organs and the largest digestive gland in the human body. It is located behind the stomach. Its main physiological function is metabolism and digestion. Among them, acute pancreatitis is the most common disease. [0003] Acute pancreatitis is an inflammatory reaction in which pancreatic enzymes are activated in the pancreas due to a variety of etiologies, causing the pancreatic tissue to digest, edema, hemorrhage and even necrosis. It is clinically characterized by acute epigastric pain, nausea, vomiting, fever and increased blood pancreatin. The severity of the disease varies from mild to severe. The mild cases are mainly pancreatic edema, which is more co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61P1/18
CPCA61K38/1825A61P1/18
Inventor 龚方华李校堃
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com